Related Experiment Video
Updated: Sep 7, 2025
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Design, synthesis and properties of peptide inhibitors based on BRCA1856-871
Guangming Sun1, Yi Zhao1, Libo Yuan2
1College of Chemistry, Zhengzhou University, Zhengzhou 450001, China; College of Chemistry and Chemical Engineering, Henan University of Technology, Zhengzhou 450001, China.
Abstract:
Overexpression of RAD51 protein was found to increase drug resistance in breast cancer cells. Breast cancer susceptibility gene 1 (BRCA1) protein can specifically bind to RAD51 protein and regulate the expression level of RAD51 protein. Based on previous studies, eight modified peptides were obtained by modifying the N-terminus of the key peptide segment 856-871 of BRCA1 with nicotinic acid (NA) and its derivatives. The interaction of BRCA1856-871 and modified peptides with the RAD51158-180 target peptide was investigated by fluorescence and circular dichroism spectroscopies. The results showed that the binding ability of 2-TFM-NA-PP to RAD51158-180 was significantly enhanced. BRCA1856-871 and modified peptides were studied by in vitro cell experiments. The results showed that the antitumor activity of 5-TFM-NA-PP was significantly enhanced compared with BRCA1856-871.
Insights
Modified peptides targeting RAD51 protein show enhanced binding and antitumor activity in breast cancer research. These findings offer new strategies for overcoming drug resistance in cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- RAD51 protein overexpression correlates with increased drug resistance in breast cancer.
- Breast Cancer Susceptibility gene 1 (BRCA1) protein interacts with and regulates RAD51 protein levels.
Purpose of the Study:
- To investigate the interaction between modified BRCA1 peptides and RAD51.
- To evaluate the enhanced binding affinity and antitumor activity of these modified peptides.
Main Methods:
- Synthesis of eight modified peptides derived from the BRCA1 856-871 segment using nicotinic acid derivatives.
- Spectroscopic analysis (fluorescence and circular dichroism) to study peptide-protein interactions.
- In vitro cell experiments to assess antitumor efficacy.
Main Results:
- The modified peptide 2-TFM-NA-PP demonstrated significantly enhanced binding to the RAD51 158-180 target peptide.
- The modified peptide 5-TFM-NA-PP exhibited significantly enhanced antitumor activity compared to the original BRCA1 856-871 segment in vitro.
Conclusions:
- Nicotinic acid modification of BRCA1 peptides can enhance their interaction with RAD51.
- These modified peptides hold potential for developing novel therapeutic strategies against drug-resistant breast cancer.
More Related Videos
09:22Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015